FDA Grants Expanded Approval for Eli Lilly's Jaypirca in Earlier-Line CLL/SLL Treatment
核心洞察
The FDA has expanded approval for Eli Lilly's Jaypirca to include treatment of adults with relapsed or refractory chronic lymphocytic leukemia (搜索) or small lymphocytic lymphoma (搜索) who have previously been treated with a covalent BTK inhibitor.
This expanded approval allows physicians to use Jaypirca directly after a covalent BTK inhibitor, enabling earlier intervention in the treatment course for these blood cancers.
The FDA decision also converts Jaypirca's December 2023 accelerated approval for later-stage CLL/SLL into a full, traditional approval based on phase 3 study results.
Eli Lilly and Company announced that the U.S. Food and Drug Administration has expanded the approval for Jaypirca (pirtobrutinib) to include treatment of adults with relapsed or refractory chronic lymphocytic leukemia (搜索) or small lymphocytic lymphoma (搜索) (CLL/SLL) who have previously been treated with a covalent Bruton tyrosine kinase (搜索) (BTK) inhibitor. This regulatory milestone represents a significant advancement in the treatment landscape for these hematologic malignancies.
Expanded Treatment Access
The expanded approval allows Jaypirca to be used earlier in the treatment sequence, enabling physicians to prescribe the drug directly after a covalent BTK inhibitor fails. "The expanded approval will allow doctors to use Jaypirca directly after a covalent BTK inhibitor," said Jacob Van Naarden, president of Lilly Oncology. This represents a meaningful shift from the drug's previous indication, which required patients to have received at least two prior lines of therapy.
The FDA decision also converts Jaypirca's December 2023 accelerated approval for later-stage CLL/SLL into a full, traditional approval. The original accelerated approval required patients to have received at least two prior lines of therapy, including both a BTK inhibitor and a BCL-2 (搜索) inhibitor.
Clinical Foundation
The expanded approval is based on results from a phase 3 study, marking a transition from the accelerated approval pathway to full regulatory endorsement. Jaypirca is now approved as 100 milligram and 50 milligram tablets for the expanded patient population. Eli Lilly continues to study Jaypirca in patients with these cancer types across multiple phase 3 studies.
Disease Background
Chronic lymphocytic leukemia (搜索) and small lymphocytic lymphoma (搜索) are forms of slow-growing non-Hodgkin lymphoma (搜索) that develop from white blood cells known as lymphocytes. When the cancer primarily forms in the blood and bone marrow, it is referred to as CLL, and when it mainly arises in the lymph nodes, it is known as SLL.
Regulatory History and Commercial Performance
Jaypirca first received FDA approval in January 2023 for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (搜索) (MCL) after at least two lines of systemic therapy, including a BTK inhibitor, under the FDA's Accelerated Approval pathway.
The drug has demonstrated strong commercial performance, recording $337 million in revenue for the full year of 2024 and generating $358 million in sales for the nine months ended September 30, 2025. This financial success underscores the significant unmet medical need in the BTK inhibitor-resistant patient population.